Document is current
Any future updates will be listed below
-
Authors
Gupta, Navin
Zhang, Ke
Sabbisetti, Venkata
Shu, Jian
Morizane, Ryuji https://orcid.org/0000-0002-0377-5667
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (U01DK127587, DP2DK133821)
- License Information
-
More Information
Article History
Received: 13 March 2025
Revised: 26 June 2025
Accepted: 3 July 2025
First Online: 8 August 2025
Competing interests
: R.M. is an inventor on patents filed by the President and Fellows of Harvard College and Mass General Brigham (PCT/US2018/036677 licensed to Trestle Biotherapeutics, PCT/US23/73271, and PCT/US23/71029). R.M. holds a stock option in Trestle Biotherapeutics. R.M. served as a consultant to Toray Industries, and Ajinomoto. The authors declare no other competing interests.
: All experimental protocols using human cell lines were approved by the Partners Institutional Biosafety Committee (PIBC), approval numbers 2016B000044 and 2019B000050.
